Clinical characteristics and response to SIC
| Case | A | B | C |
| Respiratory symptoms | Lower | Upper and lower | Lower |
| Total IgE, kU/L | 24 | 383 | 664 |
| Eosinophils, 109/L | 0.07 | 0.25 | 0.16 |
| Specific IgE, anhydrides | Positive * | Negative | Negative |
| Specific IgE, aeroallergens | Negative | Positive† | Positive‡ |
| Baseline FEV1, L, (% of predicted values), FEV1/FVC | 3.31 (88%), 0.52 | 2.41 (69%), 0.74 | 3.90 (106 %), 0.75 |
| Peakflow diurnal variability | 20% | 16% | Not tested |
| Methacholine Challenge Test (PD20), µg§ | 268 | Negative | 261 |
| Maximum fall in FEV1/hours from challenge start | 19%/4 | 16%/12 24%/24 | 17%/9 |
| Respiratory symptoms during SIC | Lower | Lower | Lower |
*Phthalic anhydride, hexahydrophthalic anhydride, methyltetrahydrophtalic anhydride, positive >0.1 kU/L.
†Phleum pratensa, Dermatophagoides farinae, Dermatophagoides pteronyssinus, positive >0.35 kU/L.
‡Phleum pratensa, Betula verrucosa, Artemisia vulgaris, Cladosporium herbarium , positive > 0.35 kU/ L.
§Dose of metacholine that results in a 20 % fall in FEV1, positive < 400 µg .
FEV1, forced expiratory flow in 1 s; IgE, immunoglobulin E; SIC, specific inhalation challenge.